As reported by us [6–8] and other groups [9, 10], non-genotoxic targeting of the pathway using small molecules indicates that negative regulators of p53 including MDM2 contribute largely to p53 pathway dysregulation in MM. This evidence concerns the gene MDM2 and Miyoshi myopathy.